Meningococcal infections are caused by the bacterium Neisseria meningitidis. The disease is transmitted through droplets from the nose and throat of an infected person. Meningococcal conjugate vaccines are used to prevent infection with serogroups A, C, W, and Y. Meningococcal polysaccharide vaccine is used to prevent infection with serogroups A and C. Serogroup B meningococcal vaccine is used to prevent infection with serogroup B.
The global meningococcal infections vaccine market was valued at USD 1,890 million in 2018 and is projected to reach USD 2,907 million by 2030, growing at a CAGR of 7% during the forecast period. The market for children segment was valued at USD 1,037 million in 2018 and accounted for the largest share of the global market in 2018 due to high incidence rates among children below 15 years of age as compared to other age groups. The market for adults segment was valued at USD 853 million in 2018 due to high incidence rates among adults above 15 years of age as compared to other age groups. North America dominated the global meningitis vaccine market owing to higher awareness about vaccination programs among people living in this region as well as higher spending on healthcare services per capita than any other region globally which has led people living here being more aware about their health status than those residing elsewhere across the globe.
- The increasing incidence of meningitis and the need for protection against the disease are driving the growth of this market.
- The introduction of new vaccines in the market is also expected to fuel its growth.
- Increasing awareness about meningitis and its prevention among people is also expected to drive this market's growth.
- Increasing government funding for research on meningitis and other vaccine-preventable diseases.
Industry Growth Insights published a new data on “Meningococcal Infections Vaccine Market”. The research report is titled “Meningococcal Infections Vaccine Market research by Types (Meningococcal Conjugate Vaccines, Meningococcal Polysaccharide Vaccine, Serogroup B Meningococcal Vaccine), By Applications (Children, Preteens/Teens, Adults), By Players/Companies Sanofi-Pasteur, Beijing Tiantan Biological Products, Shanghai Institute of Biological Products, Wuhan Institute of Biological Products, Lanzhou Institute of Biological Products, Hualan Biological Engineering, Chongqing Zhifei Biological Products, Zhejiang Tianyuan Bio-Pharmaceutical, Walvax Biotechnology, Royal(Wuxi) Bio-Pharmaceutical”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Meningococcal Infections Vaccine Market Research Report
By Type
Meningococcal Conjugate Vaccines, Meningococcal Polysaccharide Vaccine, Serogroup B Meningococcal Vaccine
By Application
Children, Preteens/Teens, Adults
By Companies
Sanofi-Pasteur, Beijing Tiantan Biological Products, Shanghai Institute of Biological Products, Wuhan Institute of Biological Products, Lanzhou Institute of Biological Products, Hualan Biological Engineering, Chongqing Zhifei Biological Products, Zhejiang Tianyuan Bio-Pharmaceutical, Walvax Biotechnology, Royal(Wuxi) Bio-Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Meningococcal Infections Vaccine Market Report Segments:
The global Meningococcal Infections Vaccine market is segmented on the basis of:
Types
Meningococcal Conjugate Vaccines, Meningococcal Polysaccharide Vaccine, Serogroup B Meningococcal Vaccine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Children, Preteens/Teens, Adults
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi-Pasteur
- Beijing Tiantan Biological Products
- Shanghai Institute of Biological Products
- Wuhan Institute of Biological Products
- Lanzhou Institute of Biological Products
- Hualan Biological Engineering
- Chongqing Zhifei Biological Products
- Zhejiang Tianyuan Bio-Pharmaceutical
- Walvax Biotechnology
- Royal(Wuxi) Bio-Pharmaceutical
Highlights of The Meningococcal Infections Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Meningococcal Conjugate Vaccines
- Meningococcal Polysaccharide Vaccine
- Serogroup B Meningococcal Vaccine
- By Application:
- Children
- Preteens/Teens
- Adults
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Meningococcal Infections Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Meningococcal infections vaccine is a vaccine that helps protect people from meningitis, a serious infection of the membranes that cover the brain and spinal cord. Meningococcal infections can be deadly if not treated quickly. The vaccine is available as a shot or as part of a combination vaccine against other types of meningitis. It is recommended for people ages 11 to 64 years old who are at high risk for getting meningococcal infections, including those who have weakened immune systems due to cancer treatment, AIDS, or another illness.
Some of the major players in the meningococcal infections vaccine market are Sanofi-Pasteur, Beijing Tiantan Biological Products, Shanghai Institute of Biological Products, Wuhan Institute of Biological Products, Lanzhou Institute of Biological Products, Hualan Biological Engineering, Chongqing Zhifei Biological Products, Zhejiang Tianyuan Bio-Pharmaceutical, Walvax Biotechnology, Royal(Wuxi) Bio-Pharmaceutical.
The meningococcal infections vaccine market is expected to grow at a compound annual growth rate of 7%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Meningococcal Infections Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Meningococcal Infections Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Meningococcal Infections Vaccine Market - Supply Chain
4.5. Global Meningococcal Infections Vaccine Market Forecast
4.5.1. Meningococcal Infections Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Meningococcal Infections Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Meningococcal Infections Vaccine Market Absolute $ Opportunity
5. Global Meningococcal Infections Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Meningococcal Infections Vaccine Market Size and Volume Forecast by Type
5.3.1. Meningococcal Conjugate Vaccines
5.3.2. Meningococcal Polysaccharide Vaccine
5.3.3. Serogroup B Meningococcal Vaccine
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Meningococcal Infections Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Meningococcal Infections Vaccine Market Size and Volume Forecast by Application
6.3.1. Children
6.3.2. Preteens/Teens
6.3.3. Adults
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Meningococcal Infections Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Meningococcal Infections Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Meningococcal Infections Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Meningococcal Infections Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Meningococcal Infections Vaccine Demand Share Forecast, 2019-2029
9. North America Meningococcal Infections Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Meningococcal Infections Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Meningococcal Infections Vaccine Market Size and Volume Forecast by Application
9.4.1. Children
9.4.2. Preteens/Teens
9.4.3. Adults
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Meningococcal Infections Vaccine Market Size and Volume Forecast by Type
9.7.1. Meningococcal Conjugate Vaccines
9.7.2. Meningococcal Polysaccharide Vaccine
9.7.3. Serogroup B Meningococcal Vaccine
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Meningococcal Infections Vaccine Demand Share Forecast, 2019-2029
10. Latin America Meningococcal Infections Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Meningococcal Infections Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Meningococcal Infections Vaccine Market Size and Volume Forecast by Application
10.4.1. Children
10.4.2. Preteens/Teens
10.4.3. Adults
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Meningococcal Infections Vaccine Market Size and Volume Forecast by Type
10.7.1. Meningococcal Conjugate Vaccines
10.7.2. Meningococcal Polysaccharide Vaccine
10.7.3. Serogroup B Meningococcal Vaccine
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Meningococcal Infections Vaccine Demand Share Forecast, 2019-2029
11. Europe Meningococcal Infections Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Meningococcal Infections Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Meningococcal Infections Vaccine Market Size and Volume Forecast by Application
11.4.1. Children
11.4.2. Preteens/Teens
11.4.3. Adults
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Meningococcal Infections Vaccine Market Size and Volume Forecast by Type
11.7.1. Meningococcal Conjugate Vaccines
11.7.2. Meningococcal Polysaccharide Vaccine
11.7.3. Serogroup B Meningococcal Vaccine
11.8. Basis Point Share(BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Meningococcal Infections Vaccine Demand Share, 2019-2029
12. Asia Pacific Meningococcal Infections Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Meningococcal Infections Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Meningococcal Infections Vaccine Market Size and Volume Forecast by Application
12.4.1. Children
12.4.2. Preteens/Teens
12.4.3. Adults
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Meningococcal Infections Vaccine Market Size and Volume Forecast by Type
12.7.1. Meningococcal Conjugate Vaccines
12.7.2. Meningococcal Polysaccharide Vaccine
12.7.3. Serogroup B Meningococcal Vaccine
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Meningococcal Infections Vaccine Demand Share, 2019-2029
13. Middle East & Africa Meningococcal Infections Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Meningococcal Infections Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Meningococcal Infections Vaccine Market Size and Volume Forecast by Application
13.4.1. Children
13.4.2. Preteens/Teens
13.4.3. Adults
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Meningococcal Infections Vaccine Market Size and Volume Forecast by Type
13.7.1. Meningococcal Conjugate Vaccines
13.7.2. Meningococcal Polysaccharide Vaccine
13.7.3. Serogroup B Meningococcal Vaccine
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Meningococcal Infections Vaccine Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Meningococcal Infections Vaccine Market: Market Share Analysis
14.2. Meningococcal Infections Vaccine Distributors and Customers
14.3. Meningococcal Infections Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Sanofi-Pasteur
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Beijing Tiantan Biological Products
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Shanghai Institute of Biological Products
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Wuhan Institute of Biological Products
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Lanzhou Institute of Biological Products
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Hualan Biological Engineering
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Chongqing Zhifei Biological Products
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Zhejiang Tianyuan Bio-Pharmaceutical
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Walvax Biotechnology
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Royal(Wuxi) Bio-Pharmaceutical
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
